ICR Westwicke is an IPO advisory, capital markets advisory, and strategic communications firm. We provide integrated investor relations, public relations, and independent capital markets advice to small and mid-cap healthcare companies.
We work with private and public healthcare companies to help position their story properly with all critical stakeholders and to develop value-added strategies to build brand awareness, corporate reputation and enhance equity market value. Through an integrated approach, we provide a one-stop-shop for the full spectrum of communications needs across the entire corporate lifecycle from early stage start-up to mature public company.
Our background is unique. Our investor relations partners all come directly from Wall Street as former sell-side research analysts, institutional salesmen, investment bankers, equity capital markets professionals, buy-side analysts and portfolio managers, while our public relations team are former agency veterans, corporate communications executives and journalists.
Learn more
Latest Blog Posts
-
September 26th, 2022
The ‘Innovator’s Burden’: How to combat skepticism in healthcare as a first-of-its-kind company
From new treatments and technologies to platforms and diagnostics, we may be living through the greatest period of innovation in the history of healthcare. The biopharma industry’s efforts to rapidly develop multiple safe and efficacious life-saving vaccines for the Covid-19 pandemic is just the latest example of the collective appreciation for innovation and its ability […]
-
September 7th, 2022
5 Benefits of Proper Earnings Call Preparation
While quarterly earnings calls may happen routinely, they should be anything but routine. Earnings calls are your opportunity to tell your story to the world — and they’re one of the few times each year you have the chance to capture the undivided attention of your analysts and investors. So, it’s essential to make these calls […]
-
August 23rd, 2022
Is the Biotech IPO Market Coming Back? How to Prepare
The second quarter of 2022 was the weakest quarter for healthcare and biotech IPOs in more than five years. Some media headlines have predicted that it marked the bottom of the biotech market. The XBI biotech index fund, which serves as an index for many companies that are eyeing a public debut, peaked in January […]
